Market research
MDGL Madrigal Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12B
- P/E ratio
- Not available
- Analyst target
- 678.0625
- Dividend yield
- Not available
- Beta
- -1.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5588681057
- Market cap
- 12B
- P/E ratio
- Not available
- Analyst target
- 678.0625
- Dividend yield
- Not available
- Beta
- -1.0
About
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDGL discussion.
5 years, 4 months ago
Madrigal Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Madrigal Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 113.1% to $-59M since the same quarter in the previous year.
Finally, its free cash flow fell by 342.6% to $-55M since the same quarter in the previous year.
Based on the above factors, Madrigal Pharmaceuticals, Inc gets an overall score of 1/5.